• Real World DATA Information Systems

    Nov 1, 2019, 00:00

  • PMU148 CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA

    Nov 1, 2019, 00:00

  • PND7 EFFICACY OF VIRTUAL REALITY GLASSES AMONG PATIENTS WITH STROKE

    Nov 1, 2019, 00:00

  • PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PUK15 INPATIENT COST-SAVINGS FROM THE USE OF SUCROFERRIC OXYHYDROXIDE IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS61 DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION

    Nov 1, 2019, 00:00

  • PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE

    Nov 1, 2019, 00:00

  • PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA

    Nov 1, 2019, 00:00

  • PNS380 BREAST CANCER PATIENT PERSPECTIVES ON IMPORTANT SYMPTOM INFORMATION

    Nov 1, 2019, 00:00

  • PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING

    Nov 1, 2019, 00:00

  • PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PCN358 COMPARING AND VALIDATING THE OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TREATMENTS APPLIED IN HTA'S BY NOMA AND TLV

    Nov 1, 2019, 00:00

  • Infectious Disease Studies

    Nov 1, 2019, 00:00

  • PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS

    Nov 1, 2019, 00:00

  • PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS

    Nov 1, 2019, 00:00

  • PNS21 REAL WORLD EVIDENCE (RWE) IN PARTITION SURVIVAL MODELLING: IS IT THE REAL DEAL?

    Nov 1, 2019, 00:00

  • PNS309 UTILIZING MACHINE LEARNING AND ECG DATA FOR CONTINUOUS USER AUTHENTICATION OF PATIENTS DURING A CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PNS173 MEASURING DELAYS IN THE AVAILABILITY OF NEW MEDICINES WITHIN EUROPE USING A TIME-TO-PRICE INDICATOR

    Nov 1, 2019, 00:00

  • PBI46 IMPLEMENTATION OF ADALIMUMAB BIOSIMILARS IN DENMARK

    Nov 1, 2019, 00:00

  • PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS

    Nov 1, 2019, 00:00

  • RARE Regulatory

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS163 SHIFTING PARADIGM OF INTERNATIONAL REFERENCE PRICING. IS IT BENEFICIAL TO PAYERS, MANUFACTURERS OR PATIENTS?

    Nov 1, 2019, 00:00

  • Cancer - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

    Nov 1, 2019, 00:00

  • PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES

    Nov 1, 2019, 00:00

  • PUK18 THE ECONOMIC COST ASSOCIATED WITH NOCTURIA IN A WORKING-AGE POPULATION

    Nov 1, 2019, 00:00

  • PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

    Nov 1, 2019, 00:00

  • PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PGI32 EVALUATION OF THE COST-UTILITY OF THE YORK FAECAL CALPROTECTIN CARE PATHWAY

    Nov 1, 2019, 00:00

  • PCN223 A BUDGET IMPACT ANALYSIS OF A COMMUNITY-BASED SUPPORT CENTRE FOR CANCER PATIENTS AND SURVIVORS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH

    Nov 1, 2019, 00:00

  • PMD14 COST-EFFECTIVENESS ANALYSIS OF THE USE OF MICROINVASIVE SURGERY WITH ISTENT® IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • Alternative Medicine Public Health

    Nov 1, 2019, 00:00

  • PMD13 COST-UTILITY ANALYSIS OF ISTENT INJECT IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA IN JAPAN

    Nov 1, 2019, 00:00

  • PDB44 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • PND79 HOW DIFFERENT ARE MIGRAINE PATIENTS TREATED BY GENERAL PRACTITIONERS VERSUS THOSE TREATED BY NEUROLOGISTS?

    Nov 1, 2019, 00:00

  • PNS33 PUBLICATION TREND AND CITATION ANALYSIS OF ARTICLES PUBLISHED IN "VALUE IN HEALTH” BETWEEN 1998-2019

    Nov 1, 2019, 00:00

  • PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS

    Nov 1, 2019, 00:00

  • PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS

    Nov 1, 2019, 00:00

  • PCN516 EXPLORING THE CURRENT STATUS OF NEUROENDOCRINE TUMOURS: A POPULATION-BASED ANALYSIS OF EPIDEMIOLOGY, MANAGEMENT AND USE OF RESOURCES

    Nov 1, 2019, 00:00

  • PBI56 SUSTAINABLE BIOSIMILAR PROCUREMENT IN EUROPE: A REVIEW OF CURRENT POLICIES AND THEIR POTENTIAL IMPACT

    Nov 1, 2019, 00:00

  • PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS)

    Nov 1, 2019, 00:00

  • PRO35 ANALYZING THE LEVEL OF EVIDENCE REQUIRED FOR ONCOLOGY VERSUS NON-ONCOLOGY ORPHAN DRUGS AS IT RELATES TO PRICE

    Nov 1, 2019, 00:00

  • PCN145 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB IN ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION IN FRANCE

    Nov 1, 2019, 00:00

  • PMS43 DUCHENNE MUSCULAR DYSTROPHY PREVALENCE IN FIVE EUROPEAN COUNTRIES: A NOVEL INCIDENCE-BASED MODELING APPROACH USING SYSTEM DYNAMICS

    Nov 1, 2019, 00:00

  • PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PNS177 BARRIERS TO PUBLIC PRIVATE PARTNERSHIPS IMPLEMENTATION IN HEALTHCARE SECTOR IN KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PBI93 CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN60 VALUE OF NEOADJUVANT IO THERAPIES WITH OR WITHOUT ADJUVANT CANCER THERAPIES: A MODEL FRAMEWORK

    Nov 1, 2019, 00:00

  • PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD

    Nov 1, 2019, 00:00

  • PNS200 ANALYSIS OF HOSPITAL USE OF SURGERY WARDS TO OPTIMIZE HOSPITAL INFRASTRUCTURE PLANNING

    Nov 1, 2019, 00:00

  • PCN368 ADVANCED NMA TECHNIQUES IN NICE STA SUBMISSIONS

    Nov 1, 2019, 00:00

  • PNS319 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS

    Nov 1, 2019, 00:00

  • PNS204 THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS

    Nov 1, 2019, 00:00

  • PDB121 THE FINANCIAL IMPACT OF FEBUXOSTAT REIMBURSEMENT TO THE TAIWAN NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PBI63 IMPACT OF TOCILIZUMAB SUBCUTANEOUS INJECTION COMMERCIALIZATION ON PRACTICES IN THE PUBLIC HOSPITALS OF PARIS

    Nov 1, 2019, 00:00

  • PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN394 DETERMINANTS OF MANAGED ENTRY AGREEMENTS IN THE CONTEXT OF HTA; EMPIRICAL EVIDENCE FROM ONCOLOGY MEDICINES IN FOUR COUNTRIES.

    Nov 1, 2019, 00:00

  • PNS364 PATIENT INVOLVEMENT IN EUNETHTA PHARMACEUTICAL JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMU33 EPIDEMIOLOGY OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR): EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS316 USE OF GENERALISED FLUCTUATION TEST TO OPTIMISE PIECEWISE FITTING IN IMMUNO-ONCOLOGY (IO) SURVIVAL MODELLING

    Nov 1, 2019, 00:00

  • PIN35 GLOBAL ANNUAL COSTS OF PEOPLE LIVING WITH HIV IN FRANCE IN 2013 FROM A NATIONAL INSURANCE CLAIMS DATABASE (SNIIRAM)

    Nov 1, 2019, 00:00

  • PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

    Nov 1, 2019, 00:00

  • PSY25 THE RELATIONSHIP BETWEEN PEANUT ALLERGY PREVALENCE AND THE DIFFERENT DIAGNOSTIC METHODS USED, ACROSS 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PMU60 INCENTIVE STRUCTURES OF ADDITIONAL PAYMENTS FOR NEW TECHNOLOGIES IN INPATIENT CARE: DOES IT WORK?

    Nov 1, 2019, 00:00

  • PBI26 THE ECONOMIC REASON FOR THE USE OF VEDOLIZUMAB COMPARED WITH INHIBITORS OF TNF-ALPHA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON THE EXAMPLE OF MOSCOW

    Nov 1, 2019, 00:00

  • PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PMS48 270-DAYMORTALITY AND ITS PREDICTORS IN MEN WITH CONTRALATERAL HIP FRACTURE AFTER FEMORAL NECK FRACTURE

    Nov 1, 2019, 00:00

  • PMU108 LEVERAGING ELECTRONIC HEALTH RECORDS TO MEET THE REAL-WORLD EVIDENCE NEEDS OF HTA: A UK PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB97 THE EFFECT OF NIGHT EATING ON NUTRITIONAL HABITS AND QUALITY OF LIFE OF DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PCN252 RISK OF LUNG CANCER AMONG SMOKING WOMEN TREATED WITH RADIOTHERAPY FOR PRIMARY BREAST CANCER: FRENCH PROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN448 IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS

    Nov 1, 2019, 00:00

  • RW2 METHODOLOGICAL APPROACHES FOR INCORPORATING REAL-WORLD DATA (RWD) FOR OVERALL SURVIVAL (OS) INTO LONG-TERM SURVIVAL ESTIMATES: A CASE-STUDY NICE TECHNOLOGY APPRAISAL IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • PNS367 THE NATIONAL HEALTH COUNCIL PATIENT ENGAGEMENT RUBRIC: A GUIDE TO INCORPORATING THE PATIENT VOICE INTO THE HEALTHCARE ECOSYSTEM

    Nov 1, 2019, 00:00

  • PMH59 VALIDATION OF A SCREENING INSTRUMENT OF ADDICTION TO FAST FOOD IN SPANISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PNS94 ESTIMATING MISSING BASELINE SERUM CREATININE FOR ACUTE KIDNEY INJURY DIAGNOSIS IN HOSPITALISED PATIENTS

    Nov 1, 2019, 00:00

  • PDB100 EXAMINING THE TEMPORAL TRENDS IN HYPOGLYCEMIA EVENTS, TREATMENT ADHERENCE AND A1C IN PATIENTS WITH T2D IN THE US

    Nov 1, 2019, 00:00

  • PMS26 IMPACT OF CHRONIC LOW BACK PAIN ON EMPLOYMENT AND PRODUCTIVITY - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH

    Nov 1, 2019, 00:00

  • Infectious Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS281 DO SPANISH TPRS AFFECT THE NATIONAL PRICING AND REIMBURSEMENT OF DRUGS?

    Nov 1, 2019, 00:00

  • PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PNS332 DEALING WITH MISSING DATA IN TRIAL-BASED ECONOMIC EVALUATIONS: A METHODOLOGICAL SCOPING REVIEW

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN13 HANNA – REAL-WORLD EVIDENCE FROM A GERMAN, PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH NIVOLUMAB IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • PCN426 WHEN CROSS-OVER ISN'T CROSS OVER. STRATEGIES FOR HANDLING EFFECTIVE SUBSEQUENT THERAPIES IN ECONOMIC ANALYSIS OF ONCOLOGY TRIALS

    Nov 1, 2019, 00:00

  • PDB129 PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS IN PEOPLE WITH HEPATIC ENCEPHALOPATHY IN ENGLAND

    Nov 1, 2019, 00:00

  • PCV43 BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER FOR THE TREATMENT OF LARGE VESSEL STROKES: A U.S. PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIN3 SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS

    Nov 1, 2019, 00:00

  • PDB124 BURDEN OF HEART FAILURE IN PATIENTS WITH DIABETES IN ENGLAND

    Nov 1, 2019, 00:00

  • PIN113 EU MARKET ACCESS PATHWAYS FOR VACCINES: DEFINITION OF COUNTRY ARCHETYPES USING MATHEMATICAL CLUSTERING

    Nov 1, 2019, 00:00

  • PRO147 MAPPING PROQOLID TO RARE DISEASES: A ON-GOING COLLABORATION BETWEEN MAPI RESEARCH TRUST AND ORPHANET

    Nov 1, 2019, 00:00

  • PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    Nov 1, 2019, 00:00

  • PCN328 CHANGING EPIDEMIOLOGY AND TREATMENT ALGORITHM IN PANCREATIC CANCER IN GERMANY 2017-2018

    Nov 1, 2019, 00:00

  • PIN57 ECONOMIC EVALUATION OF AN ELECTRONIC HEALTH RECORD ALERT BY AGE IN PRIMARY CARE FOR THE DETECTION OF PATIENTS WITH CHRONIC HEPATITIS C

    Nov 1, 2019, 00:00

  • PMU74 FIRST 27 MONTHS OF CONDITIONAL REIMBURSEMENT IN FINLAND

    Nov 1, 2019, 00:00

  • PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIO ...

    Nov 1, 2019, 00:00

  • PDG47 STATUS QUO OF PHARMACEUTICAL CARE SYSTEM IN PRIMARY HEALTH CARE INSTITUTIONS OF CHINA——A LARGE SAMPLE SURVEY ON PRIMARY HEALTH CARE INSTITUTIONS OF JANGSU PROVINCE

    Nov 1, 2019, 00:00

  • PNS115 BARRIERS TO TRANSPARENCY IMPROVEMENT OF HOSPITALS PERFORMANCE: A QUALITATIVE STUDY IN IRAN

    Nov 1, 2019, 00:00

  • PGI49 CHANGES IN HEALTH RELATED QUALITY OF LIFE IN CROHN'S DISEASE PATIENTS FOLLOWING MINDFULNESS-BASED COGNITIVE INTERVENTION: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2019, 00:00

  • Drugs Generics - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS206 AIM FOR THE STARS, REACH THE MOON? A SIMPLE STRATEGY TO IMPROVE ADDITIONAL BENEFIT OUCTOMES IN GERMANY?

    Nov 1, 2019, 00:00

  • PRO64 MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION

    Nov 1, 2019, 00:00

  • PMH70 DIRECT HEALTHCARE COSTS FOR THE MANAGEMENT OF PATIENTS WITH OPIOID USE DISORDER TREATED WITH METHADONE AND BUPRENORPHINE/NALOXONE IN REAL-WORLD SETTING IN SPAIN. COSTEDOPIA STUDY

    Nov 1, 2019, 00:00

  • PCN148 COST-UTILITY OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1+ NSCLC PATIENTS: AN AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE

    Nov 1, 2019, 00:00

  • PUK29 DEVELOPING A MAPPING ALGORITHM TO PREDICT EQ-5D VALUES FROM SYMPTOM SCALES IN PATIENTS WITH BLADDER PAIN SYNDROME

    Nov 1, 2019, 00:00

  • PCN510 HEALTHCARE RESOURCE UTILISATION (HCRU) ASSOCIATED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLISATION (TACE) TREATMENT IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS IN EUROPE

    Nov 1, 2019, 00:00

  • PCV123 DETERMINANTS OF POOR QUALITY OF LIFE AND HIGH HEALTH CARE RESOURCE CONSUMPTION IN HEART FAILURE PATIENTS IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PCN10 A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

    Nov 1, 2019, 00:00

  • RARE Process of Care

    Nov 1, 2019, 00:00

  • PNS221 ANALYSIS OF HTA DOSSIERS SUBMISSION AND RECOMMENDATION REPORTS FOR DRUG PROCUREMENT AND REIMBURSMENT IN UKRAINE

    Nov 1, 2019, 00:00

  • Injury Trauma - Organizational Practices

    Nov 1, 2019, 00:00

  • PND64 EPIDEMIOLOGY OF CHRONIC MIGRAINE: A REAL-WORLD STUDY IN PRIMARY CARE IN ITALY

    Nov 1, 2019, 00:00

  • PDG63 ASSESMENT OF ACCESS TO INNOVATIVE MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PMU17 COSTS ASSOCIATED WITH THE MANAGEMENT OF CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA IN ADULT PATIENTS UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

    Nov 1, 2019, 00:00

  • PIN137 THE USE OF MULTI-YEAR AGE GROUPS IN VACCINATION MODELS BIAS THE RESULTS FOR VACCINATED INDIVIDUALS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS

    Nov 1, 2019, 00:00

  • PMD38 THE CLINICAL AND ECONOMIC ANALYSES OF VIDEO ASSISTED THORACOSCOPIC SURGERY FOR LOBECTOMY: EXPERIENCE FROM A TOP ACADEMIC MEDICAL CENTER IN CHINA

    Nov 1, 2019, 00:00

  • PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY

    Nov 1, 2019, 00:00

  • PMS16 EFFECTS OF HYDROXYCHLOROQUINE ON THROMBOSIS FACTORS AND INFLAMMATORY CYTOKINES IN PATIENTS WITH ELDERLY RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PRO63 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM CANADA AND THE US

    Nov 1, 2019, 00:00

  • PRS37 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED CHRONIC COUGH: 2018 CHRONIC COUGH SURVEY

    Nov 1, 2019, 00:00

  • PRO54 ECONOMIC BURDEN OF CARE AND TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: TWO SYSTEMATIC LITERATURE REVIEWS

    Nov 1, 2019, 00:00

  • Infectious Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PRO141 ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS

    Nov 1, 2019, 00:00

  • PNS230 CALL FOR EFFECTIVE GUIDANCE: ASSESSMENT OF PHARMACOTHERAPEUTIC GUIDELINES IMPLEMENTATION

    Nov 1, 2019, 00:00

  • PIN79 ECONOMIC EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN CHINESE HOSPITALS

    Nov 1, 2019, 00:00

  • PCV131 EVALUATION OF PRESCRIBING TRENDS AND ASSESSMENT OF DRUG RELATED PROBLEMS IN PATIENTS WITH ACUTE CORONARY SYNDROME

    Nov 1, 2019, 00:00

  • PSS16 ANTI-VEGF INTRAVITREAL INJECTIONS IN PORTUGAL: THE FIRST DECADE 2007-2017

    Nov 1, 2019, 00:00

  • PDG44 JOINT HTA AND DRUG PRICING COLLABORATIONS IN EU: BY WHOM AND WHEN TO BE PURSUED?

    Nov 1, 2019, 00:00

  • PRO107 UNDERSTANDING THE PRICING AND REIMBURSEMENT (PR) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PSY56 REAL-WORLD DATA FOR HAEMOPHILIA: A SYSTEMATIC APPROACH TO IDENTIFY AND ASSESS DATA SOURCES

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN367 STOOL DNA TESTING FOR EARLY DETECTION OF COLORECTAL CANCER

    Nov 1, 2019, 00:00

  • PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS

    Nov 1, 2019, 00:00

  • PMU103 A CRITICAL REVIEW FRAMEWORK FOR THE ASSESSMENT OF EUNETHTA METHODOLOGICAL GUIDELINES TO INFORM FUTURE JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMD56 NETWORK META-ANALYSIS OF THE USE OF ISTENT® INJECT MICROINVASIVE SURGERY IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS

    Nov 1, 2019, 00:00

  • PMU78 APPLICATION OF MACHINE LEARNING TECHNIQUES IN EARLY DISEASE DETECTION: A REVIEW

    Nov 1, 2019, 00:00

  • PMU140 A COMPREHENSIVE CATALOGUE OF EQ-5D SCORES IN CHRONIC DISEASE: RESULTS OF A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI38 INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION...

    Nov 1, 2019, 00:00

  • PBI6 WHAT IS THE APPROPRIATE DISCOUNT RATE IN ECONOMIC EVALUATIONS OF GENE THERAPIES (GT)?

    Nov 1, 2019, 00:00

  • PNS14 TOWARDS CONSISTENCY AND COHERENCE IN UNDERSTANDING THE ECONOMIC IMPACT OF DISEASE

    Nov 1, 2019, 00:00

  • PDB125 PREDICTING NASH PATIENTS USING INNOVATIVE MACHINE LEARNING TECHNIQUES

    Nov 1, 2019, 00:00

  • PNS324 A NOVEL APPROACH OF USING GRAPHICAL REPRESENTATION OF EQ-5D-3L DIMENSIONS, LEVELS, AND HEALTH STATES FOR ILLITERATE RESPONDENTS IN VALUATION STUDIES - AN EXAMPLE FROM MOROCCO

    Nov 1, 2019, 00:00

  • PCN159 COST-UTILITY ANALYSIS OF TRIFLURIDINE/TIPIRACIL FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN

    Nov 1, 2019, 00:00

  • PSY53 PATIENT PREFERENCES IN THE TREATMENT OF HEMOPHILIA: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • PCN521 THE FINANCIAL IMPACT OF AFATINIB REIMBURSEMENT FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER: THE REAL-WORLD EVIDENCE IN TAIWAN

    Nov 1, 2019, 00:00

  • PMU128 MY DAUGHTER LOVES THE NEW PENS!: QUANTIFYING THE PATIENT EXPERIENCE WITH MACHINE READING AND APPLIED SEMANTIC COMPUTING

    Nov 1, 2019, 00:00

  • PCV19 COMPARATIVE RISK OF HEART FAILURE HOSPITALIZATIONS ASSOCIATED WITH DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN320 ADMINISTRATIVE OVERSIGHT SHORTENS WAIT-TIME TO BEGIN RADIOTHERAPY IN THE PUBLIC SYSTEM

    Nov 1, 2019, 00:00

  • PCN287 THE ROLE OF EFFICACY AND EFFECTIVENESS ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS IN DETERMINING TENDERING RANKS FOR ONCOLOGY DRUGS IN DENMARK NORWAY

    Nov 1, 2019, 00:00

  • PRS19 BURDEN OF DISEASE OF FIBROSING INTERSTITIAL LUNG DISEASES IN EUROPE: THE BUILDUP PROJECT

    Nov 1, 2019, 00:00

  • PIH58 THE EFFECT OF LONG-LASTING INTAKE OF MG AND B12ON THE MOTHER AND THE INTRA-UTERINE DEVELOPMENT OF THE FOETUS AS WELL AS THE OUTCOME OF DELIVERY

    Nov 1, 2019, 00:00

  • PGI31 SENSITIVITY OF INCREASING BODY WEIGHT IN PATIENTS WITH COLLITIS ULCEROSA TO TOTAL COST OF TREATMENT

    Nov 1, 2019, 00:00

  • Cancer - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCV12 ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH HISTORY OF MYOCARDIAL INFARCTION IN FRANCE USING SNDS DATABASE

    Nov 1, 2019, 00:00

  • PRS43 SOCIAL BURDEN AND MEDICAL COST OF COPD IN KOREA

    Nov 1, 2019, 00:00

  • PCV83 EPIDEMIOLOGY OF STABLE CORONARY ARTERY DISEASE AND OF PERIPHERAL ARTERY DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS130 ANALYSIS OF LENGTH OF STAY AND COST OF INPATIENT MEDICAL CARE IN RUSSIAN DRG MODEL IN 2018

    Nov 1, 2019, 00:00

  • PCN4 DINUTUXIMAB BETA WITH ISOTRETINOIN VERSUS ISOTRETINOIN ALONE IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: IMPACT ON LONG-TERM SURVIVAL

    Nov 1, 2019, 00:00

  • PNS24 NORDIC COLLABORATIONS ON PROCUREMENT AND HEALTH TECHNOLOGY ASSESSMENT: CONCEPTS, COMPONENTS, AND OUTLOOK

    Nov 1, 2019, 00:00

  • PIN143 MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN TUBERCULOSIS PATIENTS USING SPECIFIC AND GENERIC INSTRUMENTS

    Nov 1, 2019, 00:00

  • PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PDG56 BIOSIMILAR MARKET DYNAMICS IN KOREA

    Nov 1, 2019, 00:00

  • PUK38 PATTERN OF TREATMENT AND HEALTHCARE COSTS OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS: A REAL-WORLD EVIDENCE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN180 EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ + CARBOPLATIN + ETOPOSIDE VS. CARBOPLATIN + ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • NO Specific Disease - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PNS121 PRIVATE HEALTH INSURANCE COLLABORATION WITH PHARMACEUTICAL COMPANIES IN EGYPT

    Nov 1, 2019, 00:00

  • PIH46 COST EFFECTIVENESS ANALYSIS FOR A MULTI-FACTORIAL INTERVENTION FOR ELDERLY INPATIENTS WITH DELIRIUM, UTILIZING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES

    Nov 1, 2019, 00:00

  • PBI5 IS ICER INCREASING INFLUENCE IN THE USA OVER TIME?

    Nov 1, 2019, 00:00

  • PCN110 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF MALIGNANT MELANOMA OF SKIN IN HUNGARY: COST OF ILLNESS PILOT STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN277 INTER-REGIONAL INEQUALITY IN ITALIAN HEALTHCARE DELIVERY AFFECTS CHOICE OF SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PDG100 PARENTERAL PREPARATIONS STEWARDSHIP IN A TEACHING HOSPITAL IN NIGERIA

    Nov 1, 2019, 00:00

  • PCV106 ANTIHYPERTENSIVE AGENT UTILIZATION AMONG PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS

    Nov 1, 2019, 00:00

  • PMH30 COST-UTILITY ANALYSIS OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSION DISORDERS IN CHINA

    Nov 1, 2019, 00:00

  • VALUE Assessment of Medical Technology

    Nov 1, 2019, 00:00

  • PCV11 BURDEN OF HOSPITALISATIONS/READMISSIONS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION – A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV145 ASSOCIATION BETWEEN NICORANDIL AND GASTROINTESTINAL ULCERS: A POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PUK35 THE BURDEN OF INCONTINENCE IN A REAL-WORLD DATA ENVIRONMENT - INSIGHTS FROM A DIGITAL PREVENTION COMPANION

    Nov 1, 2019, 00:00

  • PNS118 DEVELOPMENT AND POTENTIALS OF HEALTH TECHNOLOGY ASSESSMENT SYSTEM IN KAZAKHSTAN.

    Nov 1, 2019, 00:00

  • PCN2 REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE: PRELIMINARY RESULTS FROM A REGISTRY

    Nov 1, 2019, 00:00

  • PMS47 SIZING THE PATIENT POTENTIAL FOR DISEASE MODIFYING OSTEOARTHRITIS THERAPIES IN USA AND EU MARKETS

    Nov 1, 2019, 00:00

  • PMU66 TIMEFRAME FOR DRUG MARKETING AUTHORIZATION IN EUROPE

    Nov 1, 2019, 00:00

  • PRS13 COST-UTILITY ANALYSIS OF MACITENTAN IN COMPARISON WITH BOSENTAN IN PULMONARY ATRIAL HYPERTENSION (PAH)

    Nov 1, 2019, 00:00

  • HT4 INCLUSION OF PATIENT INPUT IN VALUE AND HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2019, 00:00

  • PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PDB39 INSULIN PRICE FLUCTUATION IN THE USA BETWEEN JULY 2017 AND JULY 2019

    Nov 1, 2019, 00:00

  • PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2019, 00:00

  • PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES

    Nov 1, 2019, 00:00

  • PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS164 PHARMACOECONOMIC ASSESSMENT AND DRUG COSTS OF TREATMENTS FOR CANCER AND RARE DISEASES IN IRELAND

    Nov 1, 2019, 00:00

  • PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS

    Nov 1, 2019, 00:00

  • PIN76 BUDGET IMPACT OF CEFTAZIDIME AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTION AND HOSPITAL-ACQUIRED PNEUMONIA IN SINGAPORE

    Nov 1, 2019, 00:00

  • PCN443 INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB

    Nov 1, 2019, 00:00

  • PSY3 DISEASE BURDEN OF RHEUMATOID ARTHRITIS IN CHINA

    Nov 1, 2019, 00:00

  • PBI51 TRENDS IN THE THERAPEUTIC BIOLOGICS ATHORIZED BY FDA, EMA AND THE SAUDI FDA IN THE PERIOD 1996-2018

    Nov 1, 2019, 00:00

  • PIN6 EVALUATION OF DIRECT-ACTING ANTIVIRALS RETREATMENT IN NON-SUSTAINED VIROLOGICAL RESPONDERS

    Nov 1, 2019, 00:00

  • Mental Health - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PBI90 THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES

    Nov 1, 2019, 00:00

  • PND111 DESIGN OF THE INDIVIDUALISED MEMORY DEPENDENT QUALITY OF LIFE (MEMORYDQOL) AND THE MEMORY TREATMENT SATISFACTION QUESTIONNAIRE (MEMORYTSQ) FOR PEOPLE WITH DEMENTIA USING EXISTING DQOL AND TSQ TEMPLATES AND ITEM LIBRARIES

    Nov 1, 2019, 00:00

  • PSY2 SYSTEMIC LUPUS ERYTHEMATOSUS: A TARGETED LITERATURE REVIEW OF ECONOMIC BURDEN WORLDWIDE

    Nov 1, 2019, 00:00

  • PCN436 RESPONSIVENESS OF THE EQ-5D-5L AND EORTC QLU-C10D IN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PMH15 BUDGET IMPACT ANALYSIS OF SCHIZOPHRENIA TREATMENT IN INDONESIA

    Nov 1, 2019, 00:00

  • PGI5 COLECTOMY FOR ULCERATIVE COLITIS IN THE UK: A REVIEW OF INCIDENCE AND COMPLICATIONS

    Nov 1, 2019, 00:00

  • PND60 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH INCIDENT MIGRAINE INITIATING TREATMENT - A COHORT STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK

    Nov 1, 2019, 00:00

  • PRO44 THE ECONOMIC IMPACT AND HEALTH-RELATED QUALITY OF LIFE OF SPINAL MUSCULAR ATROPHY (SMA). AN ANALYSIS ACROSS THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • Infectious Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • Adherence, Persistence and Compliance Studies

    Nov 1, 2019, 00:00

  • PR4 TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM - VERSION 1.4): CEILING AND FLOOR EFFECTS, RELIABILITY AND CONSTRUCT VALIDITY

    Nov 1, 2019, 00:00

  • PNS276 DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?

    Nov 1, 2019, 00:00

  • PCN199 COST-UTILITY ANALYSIS OF THE BI-, QUADRI-, AND NONA-VALENT HPV-VACCINE: A DECISION ANALYTIC MODEL

    Nov 1, 2019, 00:00

  • PUK33 PATIENT INSIGHTS FOR COMPLEMENT 3 GLOMERULOPATHY (C3G) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN58 FOUR-STATE MARKOV MODEL FOR IMMUNO-ONCOLOGIC THERAPIES

    Nov 1, 2019, 00:00

  • PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

    Nov 1, 2019, 00:00

  • PUK25 THE EFFECTIVENESS OF A DIGITAL PELVIC FLOOR TRAINING PROGRAM IN THE TREATMENT OF URINARY INCONTINENCE - A REAL WORLD EVALUATION

    Nov 1, 2019, 00:00

  • PCN284 PRESCRIBING TRENDS ACROSS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER IN IRELAND

    Nov 1, 2019, 00:00

  • PIN20 EXPECTED COST-EFFECTIVENESS OF HIGH DOSE VERSUS ADJUVANTED STANDARD DOSE TRIVALENT INFLUENZA VACCINES IN ENGLAND AND WALES: ASSESSMENTS USING DIRECT AND INDIRECT COMPARATIVE EFFECTIVENESS DATA

    Nov 1, 2019, 00:00

  • PMS6 QUALITY OF LIFE OF PATIENTS UNDERWENT IMPLANTATION OF KNEE ENDOPROSTHESIS

    Nov 1, 2019, 00:00

  • Neurological Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ΜCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT

    Nov 1, 2019, 00:00

  • PCV88 PHARMACY COLLECTION OF PRESCRIBED SECONDARY PREVENTIVE DRUG THERAPY AFTER MYOCARDIAL INFARCTION - A NORWEGIAN NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS338 DEVELOPMENT, VALIDATION AND ASSESSMENT OF RELIABILITY OF DDQ-KAP 16 QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PNS264 AN ASSESSMENT OF THE RECOMMENDATIONS MADE BY NICE'S MEDICAL TECHNOLOGIES EVALUATION PROGRAMME, AND WHETHER THE RECOMMENDATIONS SUPPORT MTEP'S STATED AIMS.

    Nov 1, 2019, 00:00

  • PIT10 THE INCREMENTAL COST OF TRAUMATIC BRAIN INJURY DURING THE FIRST YEAR AFTER A ROAD TRAFFIC ACCIDENT IN BELGIUM

    Nov 1, 2019, 00:00

  • PIH10 ANALYSING PRESCRIBING PATTERNS AND COSTS OF DRUG TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PMS73 DEPRESCRIBING OF ANALGESICS AND REPLACEMENT WITH PHYSIOTHERAPY IN THE DEPARTMENT OF ORTHOPEDICS FOR KNEE OSTEOARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • PBI45 UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

    Nov 1, 2019, 00:00

  • PDB41 HOW ECONOMIC ANALYSIS INCREASE AWARENESS ON CLINICAL SERVICE, A CASE OF DIABETES MELLITUS AT A TEACHING HOSPITAL IN MYANMAR

    Nov 1, 2019, 00:00

  • PGI22 HEALTH ECONOMIC EVALUATION OF EARLY LAPAROSCOPIC CHOLECYSTECTOMY FOR THE PATIENT WITH GALLSTONE DISEASE. A MICRO-COSTING ANALYSIS

    Nov 1, 2019, 00:00

  • PCN129 COST STRUCTURE ANALYSIS: DRUG THERAPY OF PATIENTS WITH STOMACH CANCER IN MOSCOW. ANALYSIS OF PATIENT DETECTION

    Nov 1, 2019, 00:00

  • PSU35 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A COMMERCIAL CLAIMS DATABASE STUDY WITH TWO-YEAR FOLLOW-UP

    Nov 1, 2019, 00:00

  • PBI65 ASSESSMENT OF WILLINGNESS TO PAY IN A RAPIDLY INCREASING BIOLOGICS MARKET FOR RESPIRATORY DISEASES

    Nov 1, 2019, 00:00

  • PMD51 EVALUATING THE USE AND OUTCOMES OF DIGITALLY ASSISTED VITREO-RETINAL SURGERY: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS41 A PRAGMATIC METHOD FOR COSTING IMPLEMENTATION STRATEGIES USING THE TIME-DRIVEN ACITVITY-BASED COSTING

    Nov 1, 2019, 00:00

  • PMU142 ASSESSING THE HUMAN AND ECONOMIC BURDEN OF SHORT STATURE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN419 THE USE OF INDIVIDUAL PATIENT-LEVEL DATA (IPD) TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS) IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PCN380 A TARGETED REVIEW EVALUATING UNCERTAINTY IN SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS FOR TREATMENTS APPROVED FOR USE SINCE THE INTRODUCTION OF THE 'NEW' CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • PND14 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WHO FAILED TO VALPROIC ACID TREATMENT

    Nov 1, 2019, 00:00

  • PUK2 A SYSTEMATIC REVIEW ASSESSING THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PCN414 INCLUSION OF SUBSEQUENT TREATMENTS WITH CURATIVE INTENT IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PARTITIONED SURVIVAL MODELS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PGI19 COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE

    Nov 1, 2019, 00:00

  • PNS170 CHEAP OR TIMELY DRUG? PRACTICAL IMPACT OF EXTERNAL REFERENCE PRICING POLICY IN THE EUROPEAN UNION

    Nov 1, 2019, 00:00

  • PCN400 ONCOLOGY-RELATED HTA DECISIONS IN GERMANY, FRANCE, SPAIN AND THE UK: ASSESSMENT OF SIMILARITIES AND DIFFERENCES

    Nov 1, 2019, 00:00

  • PMU48 PR PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PRO105 A REVIEW OF SIX YEARS OF THE NICE HIGHLY SPECIALISED TECHNOLOGY (HST) PROGRAMME

    Nov 1, 2019, 00:00

  • PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS

    Nov 1, 2019, 00:00

  • PIN65 COST-EFFECTIVENESS ANALYSIS ON ELDERLY PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS: CHALLENGING THE DUTCH HEALTH COUNCIL'S ADVICE

    Nov 1, 2019, 00:00

  • PSU11 ROBOTIC VS LAPAROSCOPIC RIGHT HEMICOLECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PRS69 TREATMENT OF COPD PATIENTS IN GERMANY AND THE NEED FOR THERAPY ESCALATION: A CLAIMS DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PCN127 NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE TRIPLETS DRD AND KRD FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA IN THE BRAZILIAN PRIVATE SYSTEM

    Nov 1, 2019, 00:00

  • PMU11 MAIN WEAKNESSES AND PROBLEMATICS OF CYBERSECURITY IN MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PDG50 PHARMACEUTICAL PRICING POLICIES IN QATAR AND LEBANON: NARRATIVE REVIEW AND DOCUMENT ANALYSIS

    Nov 1, 2019, 00:00

  • PND80 HEALTHCARE UTILISATION AND PERCEIVED HEALTH NEEDS OF MULTIPLE SCLEROSIS PATIENTS IN GREECE: EVIDENCE FROM A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS

    Nov 1, 2019, 00:00

  • PDB40 PREDICTIVE ANALYSIS OF COST AND CAPACITY EFFECTS OF THE DIGITALIZED SECONDARY CARE SERVICES FOR INSULIN-DEPENDENT DIABETES PATIENTS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • PND115 PATIENT REALITIES IN MIGRAINE. LITERATURE REVIEW ENHANCED BY SOCIAL MEDIA

    Nov 1, 2019, 00:00

  • PNS231 MANAGED ENTRY AGREEMENTS FOR PRESCRIPTION DRUGS IN SWEDEN

    Nov 1, 2019, 00:00

  • PCV134 MOBILE HEALTH TECHNOLOGY PERCEPTIONS AND USER EXPERIENCE AMONG ATRIAL FIBRILLATION PATIENTS: A SOCIAL MEDIA LISTENING STUDY

    Nov 1, 2019, 00:00

  • PIN153 HEALTH OUTCOMES AND HEALTH SYSTEM COSTS ASSOCIATED WITH SEPSIS: A POPULATION-BASED, RETROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • PND33 THE CLINICAL AND ECONOMIC BURDEN OF OBSTRUCTIVE SLEEP APNEA IN ADULTS: A COST-OF-ILLNESS ANALYSIS

    Nov 1, 2019, 00:00

  • PCV16 MULTIPLE STATISTICAL APPROACHES IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): THE EXAMPLE OF NAXOS, A LARGE FRENCH CER

    Nov 1, 2019, 00:00

  • PRO74 TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS

    Nov 1, 2019, 00:00

  • PRS73 POLLEN EXPOSURE AND ASTHMA-RELATED HEALTHCARE RESOURCE UTILIZATION IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PATIENT-LEVEL CLAIMS AND LINKED WEATHER DATA

    Nov 1, 2019, 00:00

  • PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE.

    Nov 1, 2019, 00:00

  • PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PMU22 BROADER ECONOMIC BURDEN OF SMOKING ATTRIBUTABLE DISEASES IN GREECE

    Nov 1, 2019, 00:00

  • PND67 IDENTIFICATION AND CHARACTERIZATION OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS ADULT PATIENTS BASED ON THE SNIIRAM DATABASE

    Nov 1, 2019, 00:00

  • PMU71 EFFECTIVE IMPLEMENTATION OF BIOSIMILAR MEDICINE AT PATENT EXPIRATION TO ACHIEVE OPTIMAL FINANCIAL GAIN: BEST PRACTICE MODEL WITH ADALIMUMAB AS CASE

    Nov 1, 2019, 00:00

  • PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE

    Nov 1, 2019, 00:00

  • PCV125 DIFFERENCES ACROSS HEART FAILURE PATIENTS' CHARACTERISTICS, DISEASE EXPERIENCE AND QUALITY OF LIFE IN SHANGHAI COMPARED WITH REST OF CHINA

    Nov 1, 2019, 00:00

  • PCN313 REAL-WORLD DATA ON THE USE OF ANTINEOPLASTIC PHARMACOTHERAPY REGIMENS AMONG PATIENTS WITH SKIN MELANOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN371 A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PRO55 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS COMPARED WITH NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PCV126 PATIENT PREFERENCES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS148 VALUE-BASED PROCUREMENT: UNDERSTANDING HOW PAYERS APPROACH AND IMPLEMENT CONTRACTING AND PROCUREMENT OF NOVEL TREATMENTS BASED ON THEIR VALUE

    Nov 1, 2019, 00:00

  • PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PNS215 IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES

    Nov 1, 2019, 00:00

  • PMU134 PATIENT CENTRICITY? PATIENT NOISE IN SOCIAL MEDIA AND SUPPORT PROGRAMS IN THE GERMAN HEALTHCARE ENVIRONMENT

    Nov 1, 2019, 00:00

  • PCN149 COST-EFFECTIVENESS ANALYSIS OF DABRAFENIB+TRAMETINIB VERSUS WATCHFUL WAITING IN THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED BRAF V600 POSITIVE STAGE III MELANOMA : A FRENCH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS274 CRITICALLY APPRAISING SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS: WHAT, WHY AND HOW? AN EXPLORATORY STUDY USING AN IRISH NATIONAL CLINICAL GUIDELINE

    Nov 1, 2019, 00:00

  • PGI24 IBD INTEGRATED MODEL OF CARE LEADS TO COST SAVINGS: A BUDGET IMPACT MODEL FOR A RUSSIAN REGION

    Nov 1, 2019, 00:00

  • PMH56 THE IMPACT OF PHYSICAL AND MENTAL STRESS ON THE PRODUCTIVITY LOSS IN JAPANESE WORKPLACE

    Nov 1, 2019, 00:00

  • PND55 ECONOMIC EVALUATION OF ENDOSCOPIC THIRD VENTRICULOSTOMY COMPARED TO SHUNTING IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS IN UZBEKISTAN

    Nov 1, 2019, 00:00

  • RE3 A PROPOSED, SCALABLE APPROACH TO IMPLEMENTING INNOVATIVE PAYMENT AGREEMENTS

    Nov 1, 2019, 00:00

  • PCN366 TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS

    Nov 1, 2019, 00:00

  • PIN92 DO INTERNATIONAL MIGRANTS FACE HIGHER BACTERIAL DRUG RESISTANCE COMPARED TO NATIVES? A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00

  • PNS262 EARLY DIALOGUE WITH NICE AND EUNETHTA: A UK PERSPECTIVE IN A POLITICALLY UNCERTAIN ERA

    Nov 1, 2019, 00:00

  • PCN263 ACCESS TO HEALTH SERVICES FOR PEOPLE WITH CANCER IN PERU: TRENDS IN SOCIO-ECONOMIC INEQUALITIES WITHIN THE FRAMEWORK OF A RESULTS-BASED BUDGETING PROGRAM

    Nov 1, 2019, 00:00

  • PMU95 IS THERE REGIONAL VARIATION IN WORSE AND SLOWER COST/QALY HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING TWO VS. ONE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK

    Nov 1, 2019, 00:00

  • PBI62 REAL-WORLD EVIDENCE ON THERAPEUTIC DRUG MONITORING OF TNF-INHIBITORS IN INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PDB37 A SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF COST-EFFECTIVENESS ANALYSIS OF INSULIN PUMPS COMPARED WITH MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS

    Nov 1, 2019, 00:00

  • PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?

    Nov 1, 2019, 00:00

  • PCN27 INTRAPATIENT COMPARISONS IN SINGLE ARM TRIALS FOR TUMOR AGNOSTIC INDICATIONS WITH APPLICATION TO ENTRECTINIB

    Nov 1, 2019, 00:00

  • PMH22 PREVALENCE OF DECISION ANALYTICAL MODELLING IN ECONOMIC EVALUATIONS OF MENTAL HEALTH INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCV34 RIVAROXABAN PLUS ASPIRIN FOR THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE

    Nov 1, 2019, 00:00

  • Drugs Generics - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PMH51 BREXANOLONE INJECTION FOR THE TREATMENT OF POSTPARTUM DEPRESSION: MINIMAL IMPORTANT DIFFERENCE AND MEANINGFUL CHANGE

    Nov 1, 2019, 00:00

  • PIN98 NATIONAL BURDEN OF SEPSIS IN INDONESIA: AN ANALYSIS BASED ON FOCAL INFECTIONS

    Nov 1, 2019, 00:00

  • PCV124 REPORTING AND QUALITY OF PATIENT PREFERENCE STUDIES: A SYSTEMATIC LITERATURE REVIEW IN THE CARDIOVASCULAR DOMAIN

    Nov 1, 2019, 00:00

  • PCV111 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN CARDIOLOGY AND DIABETOLOGY

    Nov 1, 2019, 00:00

  • PSU23 INTRAMEDULLARY NAILING OF FEMORAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PCN93 HEALTH RESOURCE UTILIZATION IN ADVANCED OVARIAN AND ENDOMETRIAL CANCER IN A UNITED STATES INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PND58 AN ECONOMIC EVALUATION ATTACHED TO A SINGLE-CENTRE, PARALLEL GROUP, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF AN THREE DAY INTENSIVE SOCIAL COGNITIVE TREATMENT (CAN DO TREATMENT) IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSI ...

    Nov 1, 2019, 00:00

  • PNS192 ASSESSING FACTORS ASSOCIATED WITH CATASTROPHIC HEALTH CARE PAYMENTS IN A WEST AFRICAN COUNTRY, CÔTE D'IVOIRE

    Nov 1, 2019, 00:00

  • PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PRO47 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PCV45 ATHEROSCLEROSIS: THE COST OF ILLNESS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS410 DATA FROM EXPANDED ACCESS PROGRAMS: TREATMENT FIRST, COLLECTION SECOND. AN OVERVIEW OF FDA AND EMA REGULATORY APPROVALS.

    Nov 1, 2019, 00:00

  • PCV7 ESTIMATION THE PHYSICAL ACTIVITY OF HEART FAILURE PATIENTS BASED ON TELEMETRY DATA

    Nov 1, 2019, 00:00

  • PDG86 ECONOMIC EVALUATION FOR PRICING AND REIMBURSEMENT OF NEW DRUGS IN SPAIN: FABLE OR DESIDERATUM?

    Nov 1, 2019, 00:00

  • PNS223 HEALTH-RELATED QUALITY OF LIFE DATA AVAILABILITY IN DRUG APPRAISALS IN FRANCE: WHERE DO WE STAND TODAY?

    Nov 1, 2019, 00:00

  • NO Specific Disease - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS169 PERSONAL MEDICAL HEALTH RECORDS REGULATION IN THE UNITED STATED, EUROPEAN UNION AND ISRAEL

    Nov 1, 2019, 00:00

  • PNS85 SELF-MEDICATION PRACTICES AMONG PATIENTS IN SAUDI ARABIA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PGI53 A QUALITATIVE STUDY EXPLORING THE BURDEN OF ULCERATIVE COLITIS AMONG CHILD, ADOLESCENT, AND ADULT PATIENTS

    Nov 1, 2019, 00:00

  • PMS56 CURRENT PATTERNS OF CARE IN THE ASSESSMENT AND TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2019, 00:00

  • PIH57 THE BLEEDING AND PELVIC DISCOMFORT SCALE: MEASURING PATIENT-REPORTED SYMPTOMS IN UTERINE FIBROIDS

    Nov 1, 2019, 00:00

  • PMH29 ESTIMATING A PREFERENCE-BASE INDEX FROM THE RECOVERING QUALITY OF LIFE MEASURE FOR ECONOMIC EVALUATION IN THE AREA OF MENTAL HEALTH: VALUATION OF REQOL-UI

    Nov 1, 2019, 00:00

  • PIN107 ASSOCIATION BETWEEN NATURAL COLD REMEDIES AND ANTIBIOTIC THERAPY

    Nov 1, 2019, 00:00

  • PNS286 SYSTEMATIC REVIEW ON THE ECONOMIC EVALUATION OF THE NON-INVASIVE PRENATAL TESTING

    Nov 1, 2019, 00:00

  • PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • PRO12 HOW DOES RISDIPLAM COMPARE IN INFANTILE ONSET SPINAL MUSCOLAR ATROPHY (SMA)? PRELIMINARY INDIRECT TREATMENT COMPARISONS BASED ON FIREFISH PART 1 DATA

    Nov 1, 2019, 00:00

  • Mental Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Injury Public Health

    Nov 1, 2019, 00:00

  • PCN296 OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

    Nov 1, 2019, 00:00

  • New Frontiers in Health Technology Assessment Research

    Nov 1, 2019, 00:00

  • PNS92 PUBLIC AWARENESS OF NURSING REFORM IN THE REPUBLIC OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE

    Nov 1, 2019, 00:00

  • PGI33 THE COST-EFFECTIVENESS OF FAECAL MICROBIOTA TRANSPLANTATION VS. ANTIBIOTICS FOR PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV67 BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • PND93 WHAT GOOD ARE DIGITAL TECHNOLOGIES IN ALZHEIMER'S DISEASE RESEARCH? - A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PRO4 IMPACT OF ENZYME REPLACEMENT THERAPY ON THE RISK OF DEVELOPING GAUCHER DISEASE-RELATED COMPLICATIONS

    Nov 1, 2019, 00:00

  • PRO99 MULTI-CRITERIA DECISION ANALYSIS (MCDA) OF ELTROMBOPAG OLAMINE IN THE TREATMENT OF PATIENTS WITH REFRACTORY SEVERE APLASTIC ANEMIA UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: A HEALTH TECHNOLOGY ASSESSMENT (HTA) ALTERNATIVE MODEL

    Nov 1, 2019, 00:00

  • PNS84 DEMOGRAPHIC FORECASTING WITH UNCERTAINTY OF POPULATION PROJECTION IN CYPRUS: A BAYESIAN PROBABILISTIC POPULATION PROJECTION STUDY

    Nov 1, 2019, 00:00

  • PDG55 RISK SHARING AGREEMENT ON PRESCRIPTION DRUGS: 5 YEARS EXPERIENCE OF THE KOREA NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PCN351 COMPARATIVE STUDY OF PFS AS PRIMARY ENDPOINT IN EUROPEAN HTA (FRANCE AND GERMANY)

    Nov 1, 2019, 00:00

  • PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS FOR TREATMENT OF MODERATE TO SEVERE PSORIASIS PATIENTS OVER 1 YEAR IN MOROCCO

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PMS11 A RETROSPECTIVE COHORT ANALYSIS OF THE BURDEN OF TOTAL KNEE ARTHROPLASTY IN JAPAN

    Nov 1, 2019, 00:00

  • Treatment Patterns Guidelines Studies

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • SP2 DISCREPANCY IN HEALTH STATE UTILITY VALUES BETWEEN COST-UTILITY ANALYSIS AND REFERENCED ORIGINAL HEALTH UTILITY STUDIES IN CARDIOVASCULAR DISEASE: A REGISTRY-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • Surgery - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIH54 HEALTH RELATED QUALITY OF LIFE OF PRE-ADOLESCENT DEAF CHILDREN WITH COCHLEAR IMPLANTS: A CONCEPTUAL DISEASE MODEL

    Nov 1, 2019, 00:00

  • PBI19 GENE THERAPIES: HOW WILL INDICATION-BASED PRICING AFFECT PATIENT ACCESS AND COST-CONTAINMENT MECHANISMS FOR PAYERS?

    Nov 1, 2019, 00:00

  • PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE

    Nov 1, 2019, 00:00

  • PIN13 FIRST EMA-EUNETHTA PARALLEL CONSULTATION FOR VACCINES

    Nov 1, 2019, 00:00

  • PRO146 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY/ACTIVITY IMPAIRMENT IN PATIENTS WITH TRANSFUSION DEPENDENT B-THALASSAEMIA IN THE UK NHS: DATA FROM A UK MULTICENTRE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • Personalized Regulatory

    Nov 1, 2019, 00:00

  • PND117 PATIENTS' PERSPECTIVES OF LIVING WITH MULTIPLE SCLEROSIS IN GREECE: AN INTERPRETIVE PHENOMENOLOGICAL ANALYSIS

    Nov 1, 2019, 00:00

  • PDG89 ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) MARKET ACCESS - A CONTINUING CHALLENGE

    Nov 1, 2019, 00:00

  • PCN100 HEALTH-ECONOMIC EVALUATION OF LUNG CANCER DRUGS: DO S AND DON TS IN FRANCE

    Nov 1, 2019, 00:00

  • PGI55 QUALITY OF LIFE AND PATIENT PREFERENCE AMONG DANISH PATIENTS WITH ULCERATIVE COLLITIS - RESULTS FROM A SURVEY STUDY

    Nov 1, 2019, 00:00

  • PNS93 THE ACTUAL NUTRITIONAL STATUS OF SCHOOLCHILDREN IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PMU111 USE OF EXTERNAL COMPARATORS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS

    Nov 1, 2019, 00:00

  • PCN325 REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS: DIVERGENCE FROM EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PIT8 ESTIMATION OF THE ECONOMIC BURDEN ASSOCIATED WITH 90-DAY COMPLICATIONS FOLLOWING INTERTROCHANTERIC HIP FRACTURE

    Nov 1, 2019, 00:00

  • PRO102 ANALYSIS OF RECENT FRENCH HTA APPRAISALS OF ORPHAN DRUGS WITH OR WITHOUT CONTRIBUTION OF PATIENTS ASSOCIATIONS

    Nov 1, 2019, 00:00

  • PNS133 BEYOND INTERNATIONAL PRICING INDEX MODEL IN THE UNITED STATES - IMPACT TO GLOBAL PRICING STRATEGIES ACCESS TO INNOVATIVE MEDICINES

    Nov 1, 2019, 00:00

  • Multiple Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • PMS36 BUDGET IMPACT ANALYSIS OF TRIPLE THERAPY AFTER FAILURE OF METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2019, 00:00

  • PRO103 THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES

    Nov 1, 2019, 00:00

  • PCN477 APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY: RESULTS FROM A TOBIT REGRESSION

    Nov 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53 (current)
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »